Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Tarsus Pharmaceuticals, Inc. (TARS) had Return on Equity of -6.12% for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$102.66M |
|
$-20.34M |
|
$6.24M |
|
$96.42M |
|
$124.84M |
|
$-22.18M |
|
$1.84M |
|
$-20.34M |
|
$-20.34M |
|
$-20.34M |
|
$-20.34M |
|
$-20.34M |
|
$-20.34M |
|
$-22.18M |
|
$-23.29M |
|
42.36M |
|
42.36M |
|
$-0.48 |
|
$-0.48 |
|
| Balance Sheet Financials | |
$474.43M |
|
$3.18M |
|
$20.57M |
|
$494.99M |
|
$90.25M |
|
$72.13M |
|
$72.13M |
|
$162.38M |
|
$332.61M |
|
$324.77M |
|
$332.61M |
|
42.21M |
|
| Cash Flow Statement Financials | |
$-50.04M |
|
$-86.65M |
|
$138.51M |
|
$97.38M |
|
$99.21M |
|
$1.83M |
|
$15.16M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.26 |
|
-- |
|
-- |
|
0.18 |
|
0.22 |
|
93.92% |
|
-21.61% |
|
-21.61% |
|
-- |
|
-19.81% |
|
-19.81% |
|
$-51.63M |
|
-- |
|
-- |
|
-- |
|
0.21 |
|
1.61 |
|
1.70 |
|
52.81 |
|
|
Return on Equity |
-6.12% |
-6.26% |
|
-4.11% |
|
-5.03% |
|
$7.88 |
|
$-1.22 |
|
$-1.18 |
|